Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC)
Ana Patiño‐García(Navarre Institute of Health Research), Luis M. Montuenga(Clinica Universidad de Navarra), Miguel F. Sanmamed(Clinica Universidad de Navarra), María J. Pajares(Universidad Pública de Navarra (UPNA)), Ignacio Melero(University of Oxford), Anna González‐Neira(Spanish National Cancer Research Centre), Alfonso Gúrpide(Clinica Universidad de Navarra), José M. López-Picazo(Navarre Institute of Health Research), Elizabeth Guruceaga(Universidad de Navarra), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Rubén Pı́o(National Institutes of Health), Javier J. Zulueta(Mount Sinai Hospital), María I. Mora(Clinica Universidad de Navarra), María E. Rodríguez-Ruiz(Navarre Institute of Health Research), Ignacio Gil‐Bazo(Navarre Institute of Health Research), Víctor Segura(Universidad de Navarra), Mapi Andueza(Clinica Universidad de Navarra), Juan P. Fusco
Cited by 0
Related Papers
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k
Cytokines in clinical cancer immunotherapy
|British Journal of Cancer|2018|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
|Immunity|2020|749
Immunostimulatory monoclonal antibodies for cancer therapy
|Nature reviews. Cancer|2007|628